Silexion Therapeutics files 8-K disclosing corporate presentation for non-deal roadshow

Silexion Therapeutics Corp

Filed Form 8-K on February 3, 2026, with Items 7.01 and 9.01.
Prepared a corporate presentation for use in investor meetings as part of a non-deal roadshow.
Presentation furnished as Exhibit 99.1 and incorporated by reference.
CEO Ilan Hadar signed the report on behalf of Silexion Therapeutics Corp.
Presentation titled 'Silencing Oncogenes at the Level of Gene Expression' for Nasdaq: SLXN.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.